

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 to 7. (canceled)

Claim 8. (withdrawn) A method of inhibiting the decrease of the content of a prostaglandin derivative in an aqueous liquid preparation, comprising storing the aqueous liquid preparation, containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water, in a resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate.

Claim 9. (withdrawn) A resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate for storing an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water.

Claims 10 and 11. (canceled)

Claim 12. (currently amended) ~~[[The]]~~ A prostaglandin-containing product ~~according to claim 10[[,]]~~ wherein the ~~prostaglandin F2 α derivative is~~ comprising an aqueous liquid preparation containing a prostaglandin F2 α derivative selected from the group consisting of 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α ; 16-(3-chlorophenoxy)-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α ; and 16-phenoxy-15-deoxy-15,15-difluoro-13,14-dihydro-17,18,19,20-tetranorprostaglandin F2 α , or an alkyl ester thereof, or a salt thereof, and a resin container containing said aqueous liquid preparation, said resin container being formed from a polymer alloy of polyethylene terephthalate and polyarylate, wherein a component ratio of polyethylene terephthalate/polyarylate is 1/2 to 2/1, thereby inhibiting a decrease of the content of the prostaglandin F2 α derivative or an alkyl ester thereof or a salt thereof in the aqueous liquid preparation.

Claim 13. (canceled)

Claim 14. (new) A prostaglandin-containing product comprising an aqueous liquid preparation containing 16-phenoxy-

15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α , or an alkyl ester thereof, or a salt thereof, and a resin container containing said aqueous liquid preparation, said resin container being formed from a polymer alloy of polyethylene terephthalate and polyarylate, wherein a component ratio of polyethylene terephthalate/polyarylate is 1/2 to 2/1, thereby inhibiting a decrease of the content of the 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α or an alkyl ester thereof, or a salt thereof in the aqueous liquid preparation.